CEO
3Sonic
3SONIC is developing an AI-powered intraoperative imaging platform that combines real-time 3D ultrasound with advanced analytics to enable rapid cancer margin assessment directly in the operating room. The system has completed a clinical proof of concept with oral cancer patients and a fully functional prototype has been constructed. By providing surgeons with immediate feedback on surgical specimens, the platform aims to improve precision and reduce treatment-related costs.
- Artificial Intelligence
- Hardware
- Healthcare Technology
- Medical Devices
- Software Only
Updated 1 month ago
Funding
Raised to date
$2.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$1.4M across 1 disclosed round
BI
€1.3M · Grant
Announced Sep 2026 · from article date
Disclosed cumulative: $1.4M
Reported total $2.1M
Incomplete round history. $673K of the $2.1M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Problem
Cancer surgeons often lack real-time tools to assess whether they have completely removed malignant tissue during an operation. Current margin assessment methods typically require sending specimens to pathology labs, causing delays that can lead to incomplete resections, additional surgeries, and increased treatment costs.
Solution
3SONIC provides an intraoperative tumor imaging platform that combines real-time 3D ultrasound with AI-driven analysis to enable rapid margin assessment of surgical specimens directly inside the operating room. The system is designed for instant use during surgery, giving surgeons immediate feedback on whether cancerous tissue remains at the resection edges. By delivering this information at the point of care, the platform supports faster surgical decisions and greater precision without interrupting the operative workflow. The technology has already demonstrated clinical efficacy through a completed proof-of-concept study with oral cancer patients, and a fully functional prototype has been constructed for further development.
Target Audience
Primary users are surgical oncologists and operating room teams who need real-time margin assessment during cancer resections, particularly those performing head and neck cancer surgeries.
Features
- Real-time 3D ultrasound imaging tailored for intraoperative use in the operating room
- AI-powered analysis engine that assists in rapid margin assessment of surgical specimens
- Fully functional prototype platform already constructed and validated
- Clinical proof of concept completed with oral cancer patients demonstrating real-world applicability
- Designed for instant, point-of-care deployment to support immediate surgical decision-making